Immunomodulatory functions of type i interferons

Nature Reviews Immunology

Volumn 12, Issue 2, 2012, Pages 125-135

  González Navajas, José M ^a,b,c   Lee, Jongdae ^a   David, Michael ^d   Raz, Eyal ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON RECEPTOR; BETA INTERFERON RECEPTOR; GAMMA INTERFERON; IMIQUIMOD; INFLAMMASOME; INTERFERON; INTERFERON REGULATORY FACTOR 3; INTERFERON REGULATORY FACTOR 7; JANUS KINASE 1; JANUS KINASE 2; LIPOPOLYSACCHARIDE; STAT1 PROTEIN; STAT2 PROTEIN; STAT3 PROTEIN; STAT4 PROTEIN; STAT5 PROTEIN; STAT6 PROTEIN; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3; VIRUS GLYCOPROTEIN;

ADAPTIVE IMMUNITY; B CELL LYMPHOMA; BACTERIAL INFECTION; CELIAC DISEASE; ENTERITIS; HAIRY CELL LEUKEMIA; HOMEOSTASIS; HUMAN; IMMUNOMODULATION; INFLAMMATION; INNATE IMMUNITY; INTERFERON PRODUCTION; KAPOSI SARCOMA; KIDNEY CARCINOMA; MELANOMA; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; REVIEW; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; T CELL LYMPHOMA;

ADAPTIVE IMMUNITY; BACTERIAL INFECTIONS; HUMANS; IMMUNITY, INNATE; IMMUNOLOGIC FACTORS; INFLAMMATION; INTERFERON-ALPHA; INTERFERON-BETA; MODELS, IMMUNOLOGICAL; VIRUS DISEASES;

EID: 84856226112     PISSN: 14741733     EISSN: 14741741     Source Type: Journal    
DOI: 10.1038/nri3133     Document Type: Review

References (152)

1. Jenner, E. Letter to the Editor. Med. Phys. J. 12 , 97-102 (1804).
2. Salaman, R. N. Protective inoculation against a plant virus. Nature 131 , 468 (1933).
3. White, P. B. Lysogenic strains of V. cholerae and the influence of lysozyme on cholera phage activity. J. Pathol. Bacteriol. 44, 276-278 (1937).
4. Hoskins, M. A protective action of neurotropic against viscerotropic yellow fever virus in Macacus rhesus. Am. J. Trop. Med. 15, 675-680 (1935).
5. Isaacs, A. & Lindenmann, J. Virus interference. I. The interferon. Proc. R. Soc. Lond. B Biol. Sci. 147, 258-267 (1957).
6. Pestka S., Krause C. D., Walter M. R. Interferons interferon-like cytokines, and their receptors Immunol. Rev. 202 8-32 2004). (Pubitemid 39576902)
7. Gad, H. H. et al. Interferon-? is functionally an interferon but structurally related to the interleukin-10 family. J. Biol. Chem. 284, 20869-20875 (2009).
8. Hacker, H. et al. Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. Nature 439 , 204-207 (2006). (Pubitemid 43083141)
9. Schafer, S. L., Lin, R., Moore, P. A., Hiscott, J. & Pi tha, P. M. Regulation of type I interferon gene expression by interferon regulatory factor-3. J. Biol. Chem. 273 , 2714-2720 (1998). (Pubitemid 28133916)
10. Monroe, K. M., McWhirter, S. M. & Vance, R. E. Induction of type I interferons by bacteria. Cell. Microbiol. 12, 881-890 (2010).
11. Trinchieri, G. Type I interferon: friend or foe? J. Exp. Med. 207 , 2053-2063 (2010).
12. Akira S. Toll-like receptors and innate immunity Adv. Immunol. 2001 78 1-56 (Pubitemid 32566017)
13. Barber, G. N. Innate immune DNA sensing pathways: STING, AIMII and the regulation of interferon production and inflammatory responses. Curr. Opin. Immunol. 23, 10-20 (2011).
14. Kawai, T. & Akira, S. The roles of TLRs, RLRs and NLRs in pathogen recognition. Int. Immunol. 21, 317-337 (2009).
15. Ishikawa, H., Ma, Z. & Barber, G. N. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature 461, 788-792 (2009).
16. Takaoka, A. et al. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature 448 , 501-505 (2007). (Pubitemid 47123520)
17. Kaiser, W. J., Upton, J. W. & Moc arski, E. S. Receptor-interacting protein homotypic interaction motif-dependent control of NF-κB activation via the DNA-dependent activator of IFN regulatory factors. J. Immunol. 181, 6427-6434 (2008).
18. Ishii, K. J. et al. TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines. Nature 451 , 725-729 (2008). (Pubitemid 351220566)
19. Chiu, Y. H., Macmillan, J. B. & Chen, Z. J. RNA polymerase III detects cytosolic DNA and induces type I interferons through the RIG-I pathway. Cell 138, 576-591 (2009).
20. Honda, K. & Taniguchi, T. IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nature Rev. Immunol. 6, 644-658 (2006). (Pubitemid 44298214)
21. Platanias, L. C. Mechanisms of type-I-and type-II-interferon-mediated signalling. Nature Rev. Immunol. 5, 375-386 (2005).
22. Fasler-Kan, E., Pansky, A., Wiederkehr, M., Battegay, M. & Heim, M. H. Interferon-α activates signal transducers and activators of transcription 5 and 6 in Daudi cells. Eur. J. Biochem. 254 , 514-519 (1998). (Pubitemid 28308101)
23. Matikainen, S. et al. Interferon-α activates multiple STAT prote ins and upregulates proliferation-associated IL-2Rα, c-myc, and pim-1 genes in human T cells. Blood 93 , 1980-1991 (1999). (Pubitemid 29128500)
24. Aaronson, D. S. & Horvath, C. M. A road map for those who don't know JAK-STAT. Science 296, 1653-1655 (2002). (Pubitemid 34579157)
25. Platanias, L. C. & Fish, E. N. Signaling pathways activated by interferons. Exp. Hematol. 27 , 1583-1592 (1999). (Pubitemid 29526742)
26. Sato, T., Selleri, C., Young, N. S. & Maciejewski, J. P. Inhibition of interferon regulatory factor-1 expression results in predominance of cell growth stimulatory effects of interferon-? due to phosphorylation of Stat1 and Stat3. Blood 90, 4749-4758 (1997). (Pubitemid 28007188)
27. Heinrich, P. C., Behrmann, I., Muller-Newen, G., Schaper, F. & Graeve, L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem. J. 334, 297-314 (1998). (Pubitemid 28448572)
28. Baker, S. J., Rane, S. G. & Reddy, E. P. Hematopoietic cytokine receptor signaling. Oncogene 26 , 6724-6737 (2007). (Pubitemid 47585098)
29. Regi s, G., Pensa, S., Boselli, D., Novelli, F. & Poli, V. Ups and downs: the STAT1:STAT3 seesaw of interferon and gp130 receptor signalling. Semin. Cell Dev. Biol. 19, 351-359 (2008).
30. Stephanou, A., Brar, B. K., Knight, R. A. & Latchman, D. S. Opposing actions of STAT-1 and STAT-3 on the Bcl-2 and Bcl-x promoters. Cell Death Differ. 7, 329-330 (2000). (Pubitemid 30192982)
31. Azare, J. et al. Constitutively activated Stat3 induces tumorigenesis and enhances cell motility of prostate epithelial cells through integrin β 6. Mol. Cell. Biol. 27 , 4444-4453 (2007). (Pubitemid 46906567)
32. Dechow, T. N. et al. Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C. Proc. Natl Acad. Sci. USA 101 , 10602-10607 (2004). (Pubitemid 38955788)
33. Dustin, M L., Singer, K. H., Tuck, D. T. & Springer, T. A. Adhesion of T lymphoblasts to epidermal keratinocytes is regulated by interferon ? and is mediated by intercellular adhesion molecule 1 (ICAM-1). J. Exp. Med. 167, 13 23-1340 (1988).
34. Yoshimura, A. Signal transduction of inflammatory cytokines and tumor development. Cancer Sci. 97 , 439-447 (2006). (Pubitemid 43811583)
35. Brucet, M., Marques, L., Sebastia n, C., Lloberas, J. & Celada, A. Regulation of murine Tap1 and Lmp2 genes in macrophages by interferon ? is mediated by STAT1 and IRF-1. Genes Immun. 5, 26-35 (2004). (Pubitemid 38967626)
36. Marques, L., Brucet, M., Lloberas, J. & Celada, A. STAT1 regulates lipopolysaccharide- and TNF-α-dependent expression of transporter associated with antigen processing 1 and low molecular mass polypeptide 2 genes in macrophages by distinct mechanisms. J. Immunol. 173 , 1103-1110 (2004). (Pubitemid 38924285)
37. Ito, S. et al. Interleukin-10 inhibits expression of both interferon α- and interferon ?-induced genes by suppressing tyrosine phosphorylation of STAT1. Blood 93, 1456-1463 (1999). (Pubitemid 29102470)
38. Yasukawa, H. et al. IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. Nature Immunol. 4, 551-556 (2003). (Pubitemid 36701338)
39. El Kasmi K. C., et al. General nature of the STAT3-activated anti-inflammatory response J. Immunol. 177 7880-7888 2006). (Pubitemid 44846303)
40. Tanabe, Y. et al. Cutting edge: role of STAT1, STAT3, and STAT5 in IFN-αβ responses in T lymphocytes. J. Immunol. 174, 609-613 (2005). (Pubitemid 40094251)
41. Qing, Y. & Stark, G. R. Alternative activation of STAT1 and STAT3 in response to interferon. J. Biol. Chem. 279 , 41679-41685 (2004). (Pubitemid 39313613)
42. Chang, E. Y., Guo, B., Doyle, S. E. & Cheng, G. Cutting edge: involvement of the type I IFN production and signaling pathway in lipopolysaccharide-induced IL-10 pr oduction. J. Immunol. 178, 6705-6709 (2007). (Pubitemid 46847391)
43. Wang, X., Chen, M., Wandinger, K. P., Williams, G. & Dhib-Jalbut, S. IFN-β -1b inhibits IL-12 production in peripheral blood mononuclear ce lls in an IL-10-dependent mechanism: relevance to IFN-β -1b therapeutic effects in multiple sclerosis. J. Immunol. 165 , 548-557 (2000). (Pubitemid 30429550)
44. Ziegler-Heitbrock, L. et al. IFN-α induces the human IL-10 gene by recruiting both IFN regulatory factor 1 and Stat3. J. Immunol. 171 , 285-290 (2003). (Pubitemid 36745299)
45. Wang, H. et al. The role of glycogen synthase kinase 3 in regulati ng IFN-β-mediated IL-10 production. J. Immunol. 186, 675-684 (2011).
46. Uddin, S. et al. Activation of the p38 mitogen-activated protein kinase by type I interferons. J. Biol. Chem. 274, 30127-30131 (1999).
47. Uddin, S. et al. The Rac1/p38 mitogen-activated protein kinase pathway is required for interferon α-dependent transcriptional activation but not serine phosphorylation of Stat proteins. J. Biol. Chem. 275, 27634-27640 (2000).
48. Li, Y. et al. Role of p38α Map kinase in type I interferon signaling. J. Biol. Chem. 279, 970-979 (2004). (Pubitemid 38082618)
49. Mayer, I. A. et al. The p38 MAPK pathway mediates the growth inhibitory effects of interferon-α in BCR-ABL-expressing cells. J. Biol. Chem. 276 , 28570-28577 (2001).
50. Ishida, H. et al. Involvement of p38 signaling pathway in interferon-α-mediated antiviral activity toward hepatitis C virus. Biochem. Biophys. Res. Commun. 321 , 722-727 (2004). (Pubitemid 39118397)
51. David, M. et al. Requirement for MAP kinase (ERK2) activity in interferon α- and interferon β -stimulated gene expression through STAT proteins. Science 269 , 1721-1723 (1995).
52. Wang, F. et al. Disruption of Erk-dependent typ e I interferon induction breaks the myxoma virus species barrier. Nature Immunol. 5, 1266-1274 (2004). (Pubitemid 41057742)
53. Uddin, S. et al. Interferon-α engages the insulin receptor substrate-1 to associate with the phosphatidylinositol 3? -kinase. J. Biol. Chem. 270 , 15938-15941 (1995).
54. Kaur, S. et al. Role of the Akt pathway in mRNA translation of interferon-stimulated genes. Proc. Natl Acad. Sci. USA 105, 4808-4813 (2008). (Pubitemid 351753828)
55. Kaur, S. et al. Dual regulatory roles of phosphatidylinositol 3-kinase in IFN signaling. J. Immunol. 181, 7316-7323 (2008).
56. Lekmine, F. et al. Activation of the p70 S6 kinase and phosphorylation of the 4E-BP1 repressor of mRNA translation by type I interferons. J. Biol. Chem. 278 , 27772-27780 (2003). (Pubitemid 36899968)
57. Lekmine, F. et al. Interferon-? engages the p70 S6 kinase to regulate phosphorylation of the 40S S6 ribosomal protein. Exp. Cell Res. 295, 173-182 (2004). (Pubitemid 38407355)
58. Matsumoto A., et al. Interferon-α-induced mTOR activation is an anti-hepatitis C virus signal via the phosphatidylinositol 3-kinase-Akt- independent pathway J. Gastroenterol. 44 856-863 2009).
59. Round J. L., Mazmanian S. K. The gut microbiota shapes intestinal immune responses during health and disease Nature Rev. Immunol. 9 313-323 2009).
60. Katakura, K. et al. Toll-like receptor 9-induced type I IFN protects mice from experimental colitis. J. Clin. Invest. 115 , 695-702 (2005). (Pubitemid 40322244)
61. Rachmilewitz, D. et al. Toll-like receptor 9 signaling mediates the anti-inflamm atory effects of probiotics in murine experimental colitis. Gastroenterology 126 , 520-528 (2004). (Pubitemid 38182309)
62. Vijay-Kumar, M. et al. Activation of Toll-like receptor 3 protects against DSS-induced acute colitis. Inflamm. Bowel Dis. 13, 856-864 (2007). (Pubitemid 47203863)
63. McFarland, A. P. et al. Localized delivery of interferon- β by Lactobacillus exacerbates experimental colitis. PloS ONE 6, e16967 (2011).
64. Abe, K. et al. Conventional dendritic cells regulate the outcome of colonic inflammation independently of T cells. Proc. Natl Acad. Sci. USA 104 , 17022-17027 (2007). (Pubitemid 350210984)
65. Hall, J. A. et al. Commensal DNA limits regulatory T cell conversion and is a natural adjuvant of intestinal immune responses. Immunity 29 , 637-649 (2008).
66. Hofmann, C. et al. T cell-dependent protective effects of CpG motifs of bacterial DNA in experimental colitis are mediated by CD11c+ dendritic cells. Gut 59, 1347- 1354 (2010).
67. Bleich, A. et al. CpG motifs of bacterial DNA exert protective effects in mouse models of IBD by antigen-independent tolerance induction. Gastroenterology 136 , 278-287 (2009).
68. Bilsborough, J., George, T. C., Norment, A. & Viney, J. L. Mucosal CD8α+ DC, with a plasmacytoid phenotype, induce differentiation and support function of T cells with regulatory properties. Immunology 108 , 481-492 (2003). (Pubitemid 36469686)
69. Levings, M. K. et al. IFN-α and IL-10 induce the differentiation of human type 1 T regulatory cells. J. Immunol. 166, 5530-5539 (2001). (Pubitemid 32374175)
70. Szabo, S. J. et al. Distinct effects of T-bet in TH1 lineage commitment and IFN-? production in CD4 and CD8 T cells. Science 295, 338-342 (2002). (Pubitemid 34074366)
71. Cho, S. S. et al. Activation of STAT4 by IL-12 and IFN-α: evidence for the involvement of ligand-induced tyrosine and serine phosphorylation. J. Immunol. 157, 4781-4789 (1996). (Pubitemid 126449551)
72. Rogge, L. et al. The role of Stat4 in species-specific regulation of Th cell development by type I IFNs. J. Immunol. 161 , 6567-6574 (1998). (Pubitemid 28562196)
73. Cousens, L. P. et al. Two roads diverged: interferon α/ β - and interleukin 12-mediated pathways in promoting T cell interferon ? responses during viral infection. J. Exp. Med. 189, 1315-1328 (1999).
74. Nguyen, K. B. et al. Critical role for STAT4 activation by type 1 interferons in the interferon-? response to viral infection. Science 297, 2063-2066 (2002).
75. Berenson, L. S., Farrar, J. D., Murphy, T. L. & Murphy, K. M. Frontline: absence of functional STAT4 activation despite detectable tyrosine phosphorylation induced by murine IFN-α. Eur. J. Immunol. 34, 2365-2374 (2004). (Pubitemid 39302794)
76. Farrar, J. D., Smith, J. D., Murphy, T. L. & Murphy, K. M. Recruitment of Stat4 to the human interferon-α/ β receptor requires activated Stat2. J. Biol. Chem. 275, 2693-2697 (2000). (Pubitemid 30082038)
77. Berenson, L. S., Gavrieli, M., Farrar, J. D., Murphy, T. L. & Murphy, K. M. Distinct characteristics of murine STAT4 activation in response to IL-12 and IFN-α. J. Immunol. 177, 5195-5203 (2006). (Pubitemid 44527592)
78. Huber, J. P. & Farrar, J. D. Regulation of effector and memory T-cell functions by type I interferon. Immunology 132, 466-474 (2011).
79. Matikainen, S. et al. IFN-α and IL-18 synergistically enhance IFN-? production in human NK cells: differential regulation of Stat4 activation and IFN-? gene expression by IFN-α and IL-12. Eur. J. Immunol. 31 , 2236-2245 (2001). (Pubitemid 32640741)
80. Strengell, M., Julkunen, I. & Matikainen, S. IFN-α regulates IL-21 and IL-21R expression in human NK and T cells. J. Leukoc. Biol. 76, 416-422 (2004). (Pubitemid 39006956)
81. Harrington, L. E. et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nature Immunol. 6 , 1123-1132 (2005). (Pubitemid 41541790)
82. Moschen A. R., Geiger S., Krehan I., Kaser A. , Tilg H. Interferon-α controls IL-17 expression in vitro and in vivo Immunobiology 213 779-787 2008
83. Qiu, H. et al. Type I IFNs enhance susceptibility to Chlamydia muridarum lung infection by enhancing apoptosis of local macrophages. J. Immunol. 181, 2092-2102 (2008).
84. Karaghiosoff, M. et al. Central r ole for type I interferons and Tyk2 in lipopolysaccharide-induced endotoxin shock. Nature Immunol. 4 , 471-477 (2003). (Pubitemid 36592440)
85. Vandenbark, A. A. et al. Interferon- β -1a treatment increases CD56bright natural killer cells and CD4+CD25+ Foxp3 expression in subjects with multiple sclerosis. J. Neuroimmunol. 215 , 125-128 (2009).
86. Zhou, X. et al. Ins tability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nature Immunol. 10, 1000-1007 (2009).
87. Oldenhove, G. et al. Decrease of Foxp3+ Treg cell number and acquisition of effector cell phenotype during lethal infection. Immunity 31, 772-786 (2009).
88. Dominguez-Villar, M., Baecher-Allan, C. M. & Hafler, D. A. Identification of T helper type 1- like, Foxp3+ regulatory T cells in human autoimmune disease. Nature Med. 17, 673- 675 (2011).
89. Schroder, K. & Tschopp, J. The inflammasomes. Cell 140 , 821-832 (2010).
90. Guarda, G. et al. Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity 34, 213-223 (2011).
91. Henry, T., Brotcke, A., Weiss, D. S., Thompson, L. J. & Monack, D. M. Type I interferon signaling is required for activation of the inflammasome during Francisella infection. J. Exp. Med. 204, 9 87-994 (2007). (Pubitemid 46798143)
92. Fernandes-Alnemri, T. et al. The AIM2 inflammasome is critical for innate immunity to Francisella tularensis. Nature Immunol. 11 , 385-393 (2010).
93. Fujita, T. et al. Induction of the transcription factor IRF-1 and interferon-β mRNAs by cytokines and activators of second-messenger pathways. Proc. Natl Acad. Sci. USA 86 , 9936-9940 (1989). (Pubitemid 20030749)
94. Rivieccio, M. A. et al. The cytokine IL-1 β activates IFN response factor 3 in human fetal astrocytes in culture. J. Immunol. 174, 3719-3726 (2005). (Pubitemid 40354083)
95. Gonzalez-Navajas, J. M. et al. Interleukin 1 recep tor signaling regulates DUBA expression and facilitates Toll-like receptor 9-driven antiinflammatory cytokine production. J. Exp. Med. 207 , 2799-2807 (2010).
96. Tseng, P. H. et al. Different mode s of ubiquitination of the adaptor TRAF3 selectively activate the expression of type I interferons and proinflammatory cytokines. Nature Immunol. 11 , 70-75 (2010).
97. Kayagaki, N. et al. DUBA: a deubiquitinase that regulates type I interferon production. Science 318, 1628-1632 (2007). (Pubitemid 350233662)
98. Lebeis, S. L., Powell, K. R., Merlin, D., Sherman, M. A. & Kalman, D. Interleukin-1 receptor signaling protects mice from lethal intestinal damage caused by the attaching and effacing pathogen Citrobacter rodentium. Infect. Immun. 77, 604-614 (2009).
99. Kojouharoff, G. et al. Neutralization of tumour necrosis factor (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice. Clin. Exp. Immunol. 107, 353-358 (1997). (Pubitemid 27049264)
100. Auerbuch, V., Brockstedt, D. G., Meyer-Morse, N., O' Riordan, M. & Portnoy, D. A. Mice lacking the type I interferon receptor are resistant to Listeria monocytogenes. J. Exp. Med. 200, 527-533 (2004). (Pubitemid 39121909)
101. Carrero, J. A., Calderon, B. & Unanue, E. R. Type I interferon sensitizes lymphocytes to apoptosis and reduces resistance to Listeria infection. J. Exp. Med. 200, 535-540 (2004). (Pubitemid 39121910)
102. Stanley, S. A., Johndrow, J. E., Manzanillo, P. & Cox, J. S. The type I IFN response to infection with Mycobacterium tuberculosis requires ESX-1-mediated secretion and contributes to pathogenesis. J. Immunol. 178 , 3143-3152 (2007). (Pubitemid 46333196)
103. Nagarajan, U. M. et al. Type I interferon signaling exacerbates Chlamydia muridarum genital infection in a murine model. Infect. Immun. 76 , 4642-4648 (2008).
104. Henry, T. et al. Type I IFN signaling constrains IL-17A/F secretion by T cells during bacterial infections. J. Immunol. 184, 3755-3767 (2010).
105. Carrero, J. A. & Unanue, E. R. Lymphocyte apoptosis as an immune subversion strategy of microbial pathogens. Trends Immunol. 27, 497-503 (2006). (Pubitemid 44499160)
106. Mancuso, G. et al. Type I IFN signaling is crucial for host resistance against different species of pathogenic bacteria. J. Immunol. 178, 3126-3133 (2007). (Pubitemid 46333194)
107. Coers, J., Vance, R. E., Fontana, M. F. & Dietrich, W. F. Restriction of Legionella pneumophila growth in macrophages requires the concerted action of cytokine and Naip5/Ipaf signalling pathways. Cell. Microbiol. 9 , 2344-2357 (2007). (Pubitemid 47365641)
108. Burger, D. & Travis, S. Conventional medical management of inflammatory bowel disease. Gastroenterology 140, 1827-1837 (2011).
109. Musch, E., Andus, T., Malek, M., Chrissafidou, A. & Schulz, M. Successful treatment of steroid refractory active ulcerative colitis with natural interferon- β - an open long-term trial. Z. Gastroenterol. 45, 1235-1240 (2007).
110. Nikolaus, S. et al. Interferon β-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study. Gut 52, 1286-1290 (2003). (Pubitemid 37026460)
111. Madsen, S. M. et al. An open-labeled, randomized study comparing systemic interferon-α-2A and prednisolone enemas in the treatment of left-sided ulcerative colitis. Am. J. Gastroenterol. 96, 1807-1815 (2001).
112. Pena Rossi, C. et al. Interferon β-1a for the maintenance of remission in patients with Crohn' s disease: results of a phase II dose-finding study. BMC Gastroenterol. 9, 22 (2009).
113. Pena-Rossi, C. et al. Clinical trial: a multicentre, randomized, double-blind, placebo-controlled, dose-finding, phase II study of subcutaneous interferon-β -1a in moderately active ulcerative colitis. Aliment. Pharmacol. Ther. 28, 758-767 (2008).
114. Gasche, C. et al. Prospective evaluation of interferon-α in treatment of chronic active Crohn 's disease. Dig. Dis. Sci. 40, 800-804 (1995).
115. Musch, E. et al. Interferon- β -1a for the treatment of steroid-refractory ulcerative colitis: a randomized, double-blind, placebo-controlled trial. Clin. Gastroenterol. Hepatol. 3 , 581-586 (2005). (Pubitemid 40824751)
116. Mitoro A., et al. Exacerbation of ulcerative colitis during α-interferon therapy for chronic hepatitis C Intern. Med. 1993 32 327-331 (Pubitemid 23282340)
117. Watanabe, T. et al. A cas e of exacerbation of ulcerative colitis induced by combination therapy with PEG-interferon α-2b and ribavirin. Gut 55 , 1682-1683 (2006). (Pubitemid 44629245)
118. Schott, E. et al. Development of ulcerative colitis in a patient with multiple sclerosis following treatment with interferon β 1a. World J. Gastroenterol. 13, 3638-3640 (2007). (Pubitemid 47162275)
119. Freeman, H. J., Chopra, A., Clandinin, M. T. & Thomson, A. B. Recent advances in celiac disease. World J. Gastroenterol. 17, 2259-2272 (2011).
120. MacDonald, T. T. & Spencer, J. Evidence that activated mucosal T cells play a role in the pathogenesis of enteropathy in human small intestine. J. Exp. Med. 167 , 1341-1349 (1988).
121. Neurath, M. F., Finotto, S. & Glimcher, L. H. The role of Th1/Th2 polarization in mucosal immunity. Nature Med. 8, 567-573 (2002). (Pubitemid 34633433)
122. Monteleone, G., Pender, S. L., Wathen, N. C. & MacDonald, T. T. Interferon-α drives T cell-mediated immunopathology in the intestine. Eur. J. Immunol. 31, 2247-2255 (2001). (Pubitemid 32785342)
123. Di Sabatino, A. et al. Evidence for the role of interferon-alfa production by dendritic cells in the Th1 response in celiac disease. Gastroenterology 133 , 1175-1187 (2007). (Pubitemid 47494463)
124. Molberg, O. et al. Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease. Nature Med. 4, 713-717 (1998). (Pubitemid 28274673)
125. Molberg, O. et al. Gliadin specific, HLA DQ2-restricted T cells are commonly found in small intestinal biopsies from coeliac disease patients, but not from controls. Scand. J. Immunol. 46, 103-109 (1997).
126. Kagnoff, M. F. Celiac disease: pathogenesis of a model immunogenetic disease. J. Clin. Invest. 117 , 41-49 (2007). (Pubitemid 46048448)
127. Ting J.P., Trowsdale J. Genetic control of MHC class II expression Cell 2002 109 S21-S33 (Pubitemid 34457849)
128. Cammarota, G., Cuoco, L., Cianci, R., Pandolfi, F. & Gasbarrini, G. Onset of coeliac disease during treatment with interferon for chronic hepatitis C. Lancet 356, 1494-1495 (2000).
129. Zheng Y., et al. Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis Nature 2007 445 648-651 (Pubitemid 46232884)
130. Nestle, F. O. et al. Plasmacytoi d predendritic cells initiate psoriasis through interferon-α production. J. Exp. Med. 202 , 135-143 (2005). (Pubitemid 41002916)
131. Dzionek, A. et al. BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-typ e lectin, mediates antigen capture and is a potent inhibitor of interferon α/β induction. J. Exp. Med. 194 , 1823-1834 (2001). (Pubitemid 34028661)
132. Hua, J., Kirou, K., Lee, C. & Crow, M. K. Functional a ssay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum. 54 , 1906-1916 (2006). (Pubitemid 43877940)
133. Kirou, K. A. et al. Activation o f the interferon-α pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum. 52, 1491-1503 (2005). (Pubitemid 40663941)
134. Blanco, P., Pal ucka, A. K., Gill, M., Pascual, V. & Banchereau, J. Induction of dendritic cell differentiation by IFN-α in systemic lupus erythematosus. Science 294, 1540-1543 (2001). (Pubitemid 33063928)
135. Jego, G. et al. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 19 , 225-234 (2003). (Pubitemid 37011337)
136. Yao, Y. et al. Neutralization of interferon-α/ β -inducible genes and downstream effect in a phase I trial of an anti-interferon-α monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum. 60 , 1785-1796 (2009).
137. Ann Marrie, R. & Rudick, R. A. Drug insight: interferon treatment in multiple sclerosis. Nature Clin. Pract. Neurol. 2, 34-44 (2006).
138. Bendtzen, K. Critical review: assessment of interferon-β immunogenicity in multiple sclerosis. J. Interferon Cytokine Res. 30, 759-766 (2010).
139. The IFNB Multiple Sclerosis Study Group. Interferon β -1b is effective in relapsing-remitting multiple sclerosis. I. Clini cal results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43, 655-661 (1993).
140. Teige, I. et al. IFN- β gene deletion leads to augmented and chronic demyelinating expe rimental autoimmune encephalomyelitis. J. Immunol. 170, 4776-4784 (2003). (Pubitemid 36519987)
141. Brod, S. A. & Burns, D. K. Suppression of relapsing experimental autoimmune encephalomyelitis in the SJL/J mouse by oral administration of type I interferons. Neurology 44, 1144-1148 (1994). (Pubitemid 24188192)
142. Prinz, M. et al. Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. Immunity 28 , 675-686 (2008).
143. Guo, B., Chang, E. Y. & Cheng, G. The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice. J. Clin. Invest. 118, 1680-1690 (2008). (Pubitemid 351632372)
144. Teige, I., Liu, Y. & Issazadeh-Navikas, S. IFN-β inhibits T cell activation capacity of central nervous system APCs. J. Immunol. 177, 3542-3553 (2006). (Pubitemid 44359885)
145. Rudick, R. A. et al. Interferon β induces interleukin-10 expression: relevance to multiple sclerosis. Ann. Neurol. 40, 618-627 (1996). (Pubitemid 26357887)
146. Ferrantini, M., Capone, I. & Belardelli, F. Interferon-α and cancer: mechanisms of action and new perspectives of clinical use. Biochimie 89, 884-893 (2007). (Pubitemid 47001642)
147. Rizza, P., Moretti, F. & Belardelli, F. Recent advances on the immunomodulatory effects of IFN-α: implications for cancer immunotherapy and autoimmunity. Autoimmunity 43, 204-209 (2010).
148. Ferrantini, M. & Belardelli, F. Gene therapy of cancer with interferon: lessons from tumor models and perspectives for clinical applications. Semin. Cancer Biol. 10, 145-157 (2000). (Pubitemid 30458474)
149. Di Pucchio T., et al. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-α results in the activation of specific CD8+ T cells and monocyte/dendritic cell precursors Cancer Res. 2006 66 4943-4951
150. Lapenta, C. et al. IFN-α-conditioned dendritic cells are highly efficient in inducing cross-priming CD8+ T cells against exogenous viral antigens. Eur. J. Immunol. 36 , 2046-2060 (2006). (Pubitemid 44251751)
151. Lapenta, C. et al. Potent immune response against HIV-1 and protection from virus challenge in hu-PBL-SCID mice immunized with inactivated virus-pulsed dendritic cells generated in the presence of IFN-α. J. Exp. Med. 198, 361-367 (2003). (Pubitemid 36987861)
152. Santodonato, L. et al. Monocyte-derived dendritic cells generated after a short-term culture with IFN-α and granulocyte-macrophage colony-stimu lating factor stimulate a potent Epstein-Barr virus-specific CD8+ T cell response. J. Immunol. 170 , 5195-5202 (2003). (Pubitemid 36554752)